In addition, following tumour-agnostic drug approvals, new molecular biomarkers such as NTRK1-3 translocations and high tumour mutational burden (TMB) have emerged in CRC as well as in other malignancies [5, 6]. Here, NTRK1 is linked to neoplasm.